Analysts Adjust Corbus Pharmaceuticals’ Earnings Projections B. Riley analysts have revised Corbus Pharmaceuticals' forecast, improving their FY2025 earnings estimate to ($3.70) per share from the previous ($5.60). This follows a Q4 2024 earnings report where the company outperformed expectations, reducing losses. The stock, however, remains volatile, with significant institutional investor activity noted.12